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Human T-lymphotropic virus 1 (HTLV-1) was the first human retrovirus to be discovered and
is the causative agent of adult T-cell leukemia/lymphoma (ATL) and the neurodegenerative
disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The
importance of microRNA (miRNA) in the replicative cycle of several other viruses, as
well as in the progression of associated pathologies, has been well established in the
past decade. Moreover, involvement of miRNA alteration in the HTLV-1 life cycle, and in
the progression of its related oncogenic and neurodegenerative diseases, has recently
come to light. Several HTLV-1 derived proteins alter transcription factor functionalities,
interact with chromatin remodelers, or manipulate components of the RNA interference
(RNAi) machinery, thereby establishing various routes by which miRNA expression can
be up- or down-regulated in the host cell. Furthermore, the mechanism of action through
which dysregulation of host miRNAs affects HTLV-1 infected cells can vary substantially
and include mRNA silencing via the RNA-induced silencing complex (RISC), transcriptional
gene silencing, inhibition of RNAi components, and chromatin remodeling. These
miRNA-induced changes can lead to increased cell survival, invasiveness, proliferation,
and differentiation, as well as allow for viral latency. While many recent studies have
successfully implicated miRNAs in the life cycle and pathogenesis of HTLV-1 infections,
there are still significant outstanding questions to be addressed. Here we will review
recent discoveries elucidating HTLV-1 mediated manipulation of host cell miRNA profiles
and examine the impact on pathogenesis, as well as explore future lines of inquiry that
could increase understanding in this field of study.
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INTRODUCTION
Human T-lymphotropic virus 1 (HTLV-1) was discovered in the
early 1980s by two-independent groups working in the United
States (Poiesz et al., 1980, 1981) and Japan (Yoshida et al., 1982).
It is a complex retrovirus and a member of the Deltaretrovirus
genus. Although there are currently four known types of HTLV,
HTLV-1 is by far the most pathogenic of the group and has the
distinction of being the first oncogenic retrovirus discovered in
humans (Mahieux and Gessain, 2007). It infects an estimated
15–20 million people worldwide and has been implicated as the
causative agent in a number of disease conditions, most notably
adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP
was first described in 1969 over a decade prior to the discovery of
HTLV-1(Mani et al., 1969). It presents with neuro-inflammatory
symptoms and incomplete paralysis of the limbs, although devel-
opment of this condition among HTLV-1 infected individuals
has been estimated at only 0.25% (Mani et al., 1969; Kaplan
et al., 1990; Kfoury et al., 2012). ATL was first characterized by
the work of Uchiyama and colleagues in 1977 (Uchiyama et al.,
1977; Gallo, 2011; Kfoury et al., 2012). Over the lifespan of an
HTLV-1 infected patient, the risk of developing ATL is 2.6–4.5%
(Tokudome et al., 1989) and the resulting cancer has an aggressive
disease course that is highly resistant to current chemotherapy
treatments (Tsukasaki et al., 2007, 2009). Due to the devastating
nature of the diseases that develop in patients infected with this
pathogen and the lack of effective treatments, it is critical to bet-
ter understand the underlying molecular mechanisms that induce
these conditions in order to develop targeted therapeutics.
The molecular mechanisms by which viruses can progress
through their life cycle and affect disease states in the host organ-
ism are diverse and our understanding of them is constantly
evolving. In the case of HTLV-1, the viral protein Tax has been
studied in depth as a both a key component for viral replication
and in the oncogenic transformation of infected cells (Jeang et al.,
1988; Pozzatti et al., 1990; Tanaka et al., 1990; Zhao and Giam,
1992; Baranger et al., 1995; Grossman et al., 1995). In addition
to viral proteins, microRNAs (miRNAs) have also been found to
play a key role in viral life cycles and related disease progression.
Over the past decade, it has been demonstrated that several rela-
tively large DNA viruses, such as the Epstein-Barr virus (EBV),
can alter host miRNA profiles and actually encode their own
viral miRNAs in order to effect changes to host cells that ben-
efit the virus (Pfeffer et al., 2004; Cameron et al., 2008; Gatto
et al., 2008). More recently, it has even been shown that other
retroviruses, such as human immunodeficiency virus (HIV-1)
and bovine leukemia virus (BLV), can effect similar changes to
host miRNAs and also encode several viral miRNAs despite their
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small genome size (Klase et al., 2007; Houzet et al., 2008; Ouellet
et al., 2008; Klase et al., 2009; Althaus et al., 2012; Kincaid et al.,
2012; Schopman et al., 2012). Moreover, several studies have also
demonstrated that HTLV-1 alters the profile of host miRNAs
(Bellon et al., 2009; Rahman et al., 2012). Examining these find-
ings regarding HTLV-1 and miRNA in connection with the recent
discoveries of miRNAmanipulation by other retroviruses demon-
strates the importance of the RNA interference (RNAi) machinery
to these related viral infections.
In this review we will examine recent studies that demonstrate
the manipulation of the host cellular miRNA profile by HTLV-
1 and its relationship to the manifestation of the oncogenic and
neurodegenerative diseases associated with this retrovirus. We
will further examine potential mechanisms of action that may be
responsible for this alteration of miRNA expression and explore
future lines of inquiry in this novel field of study. The findings
detailed here have significantly transformed our understanding
of the life cycle of the HTLV-1 virus and provide new avenues
for scientific exploration and therapeutic intervention against this
pathogen.
MicroRNA AND THE RNAi MOLECULAR MACHINERY
MicroRNA BIOGENESIS AND THE RNAi MOLECULAR MACHINERY
The biogenesis of miRNAs has been very well characterized and is
described in multiple articles (Faller and Guo, 2008; Chua et al.,
2009; Perron and Provost, 2009; Winter et al., 2009; Ying and
Lin, 2009; Van Wynsberghe et al., 2011; Yang and Lai, 2011).
MicroRNAs are genome encoded RNA hairpin structures that are
usually transcribed by RNA polymerase II (Pol II) as primary
transcripts (pri-miRNA) of up to several kilobases in length. The
pri-miRNA is produced with a 5′ 7-methyl guanosine (m7G) cap,
a 3′ poly-A tail and a structured body with one or more hair-
pin structures approximately 80 nucleotides long (Perron and
Provost, 2008). This pri-miRNA is processed in the nucleus by
the RNase III enzyme Drosha in conjunction with its associated
double-stranded RNA-binding protein, DiGeorge syndrome crit-
ical region 8 (DGCR8) (Lee et al., 2003; Cai et al., 2004; Denli
et al., 2004; Han et al., 2004). Drosha cleaves the miRNA at about
22 base pairs down-stream of the stem-loop structure to gen-
erate an approximately 60 nucleotide long pre-miRNA with a
two nucleotide 3′ overhang. The two nucleotide 3′ overhang in
the pre-miRNA is recognized by the exportin-5/Ran GTP com-
plex which then facilitates pre-miRNA export out of the nucleus
(Yi et al., 2003; Kim, 2004). In the cytoplasm, the pre-miRNA is
bound by a second RNase III enzyme, Dicer that cleaves the RNA
about two helical turns into the hairpin and degrades the terminal
loop structure (Vermeulen et al., 2005; Macrae et al., 2006; Zhang
and Zeng, 2010). Dicer acts in association with the TAR binding
protein (TRBP) (Chendrimada et al., 2005; Haase et al., 2005) and
generates a miRNA duplex of approximately 22 nucleotides with
a two nucleotide overhang at the 3′ ends of both strands.
For post-transcriptional silencing, one strand of the miRNA
duplex, the “passenger strand,” is degraded while the other, the
“guide strand,” is incorporated into the RNA-induced silencing
complex (RISC) (Kawamata and Tomari, 2010). The strand that
is less stably base-paired at the 5′ end of the duplex is usually
the guide strand (Schwarz et al., 2003). The catalytic components
of RISC are the Argonaute proteins (Ago 1–4), of which Ago2
has been shown to have endonuclease activity and can cleave
target mRNAs that show complementarity to the guide strand.
The RISC complex and the associated miRNA were first found
to bind to the 3′ UTR region of the target mRNAs, but subse-
quent studies found targeting of the 5′ UTR and coding regions
as well (Easow et al., 2007; Lytle et al., 2007; Orom et al., 2008;
Rigoutsos, 2009; Hafner et al., 2010). Nucleotides 2–7 of the
miRNA, called “the seed,” play an important role in the posi-
tioning of the RISC complex and the associated miRNA on the
target mRNA (Parker et al., 2006, 2009). The degree of comple-
mentarity between the target mRNA and the effector miRNA is a
determining factor that decides if the target mRNA is degraded
or if it is translationally repressed. Extensive complementarity
between the target and miRNA will result in mRNA degradation.
However, a low level of complementarity will result in transla-
tional repression. In mammalian cells, it has been shown that
miRNA driven destabilization and degradation of target mRNAs
is the predominant route of subsequent protein level suppression
(Guo et al., 2010). The mRNA-RISC complex is transported to
cytoplasmic structures that contain RNA remodeling components
and no translational machinery, known as the processing bod-
ies (P-bodies) and stress granules (SGs) (Liu et al., 2005; Leung
et al., 2006). However, P-bodies and SGs are not thought to be
a requirement for miRNA-mediated repression (Chu and Rana,
2006).
In addition to post-transcriptional processing, RNA medi-
ated silencing can also operate at the chromatin level to regulate
gene expression. MicroRNAs can associate with the RNA-induce
transcriptional silencing (RITS) complex and be guided to com-
plementary regions in the chromosomal DNA (Zofall and Grewal,
2006; Buhler and Moazed, 2007). In mammals, it has been found
that subunits of the RITS complex include Ago1, Ago2, and TAR
binding protein 2 (TRBP2) (Janowski et al., 2006; Kim et al.,
2006; Ahlenstiel et al., 2012). In addition to these subunits of
the RITS complex, association of Pol II with an unphosphory-
lated C-terminal domain (CTD) is requisite for association to the
complementary chromosomal DNA (Kim et al., 2006). Following
association with such genomic regions, the RITS complex recruits
factors, such as histone modifying enzymes, which alter the chro-
matin structure and induce transcriptional gene silencing (TGS)
(Verdel et al., 2004; Buhler and Moazed, 2007).
While the above-mentioned mechanism is the most com-
monly observed processing mechanism for generation of miR-
NAs, several alternate pathways have also been postulated based
largely on deep sequencing studies. These studies offer interesting
alternatives to the conventional pathway; however, the data sup-
porting them are largely preliminary and require more extensive
validation. A recent review by Yang et al. describes the vari-
ous alternate mechanisms for miRNA production (Yang and Lai,
2011).
VIRALLY ENCODED miRNAs
The crucial role of miRNAs in gene regulation makes them an
obvious target for viruses to hijack in order to regulate viral and
host gene expression. Thus, there are significant advantages for
viruses that can manipulate host miRNA profiles and/or exploit
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the RNAi machinery in order to alter host and viral gene regula-
tion. Furthermore, it has been demonstrated that viruses them-
selves generate miRNAs. Unlike viral proteins, miRNAs are not
antigenic as they can avoid the INF/PKR-induced pathway, which
is normally triggered by double stranded RNA (dsRNA) of at least
45-bp in length (Botos et al., 2009; Umbach and Cullen, 2009).
Additionally, viral miRNAs are able to successfully down-regulate
the expression of host gene products that harbor anti-viral func-
tionalities. Moreover, their small space requirement of around
200-bp of the viral genome is of significant advantage given
the tight constraints on viral genome size (Umbach and Cullen,
2009). Since the original discovery of miRNAs in EBV (Pfeffer
et al., 2004; Kok et al., 2010), approximately 436 mature viral
miRNAs have been identified across all viruses examined and
listed in the miRNA repository miRBase (Griffiths-Jones et al.,
2006, 2008; Kozomara and Griffiths-Jones, 2011).
Viral miRNAs generally have been found to follow the same
biogenesis pathways as cellular miRNA, although an alternate
mechanism of generation utilizing cellular RNA Polymerase III
(Pol III) has been observed (Bogerd et al., 2010; Kincaid et al.,
2012). Interestingly, the alternate use of Pol III to generate a viral
miRNA was observed in a HTLV-1 related deltaretrovirus, BLV.
Various techniques for the detection of viralmiRNA in an infected
cell have been employed, most of which begins with bioinfor-
matics analyses to identify stem-loop structures matching pre-
miRNA. This is followed by cDNA cloning and high-throughput
sequencing of large numbers of the resultant clones (Sullivan and
Ganem, 2005; Barth et al., 2008). These clones are subjected to
Northern blot analyses with total cellular RNA, which provides
additional confirmation. Massively parallel deep sequencing is
another widely used method for the detection of viral miRNA.
The highly sensitive SOLiD™ 3 Plus System was used to analyze
viral RNA accumulation in HIV-1-infected T lymphocytes. This
method detected numerous small RNAs that correspond to the
HIV-1 RNA genome (Schopman et al., 2012). Additionally, tar-
geted enrichment of viral small non-coding RNAs has also been
used to boost the levels of the target viral miRNAs over 100-fold
and verify HIV-1 encoded miRNAs from infected lymphocytes
(Althaus et al., 2012). The findings from these aforementioned
studies supplant previous experiments which failed to detect
miRNAs encoded in retroviruses (Lin and Cullen, 2007). The
primary improvement with these more recent sequencing stud-
ies that positively identified HIV-1 derived miRNAs is the depth
of clones sequenced or enrichment of target clones, which leads
to a greater statistical power to detect low abundance RNAs.
While no such deep sequencing or targeted enrichment stud-
ies have yet been performed with HTLV-1, the positive findings
of numerous virally encoded miRNAs from HIV-1 and other
retroviruses demonstrate the high probability that the HTLV-1
genome encodes viral miRNAs.
VIRAL MANIPULATION OF HOST CELL miRNA REGULATION
Beyond the generation of virally encoded miRNAs, infecting
viruses can also alter the expression profiles of the host cell miR-
NAs. Manipulation of cellular miRNAs represents a key mecha-
nism of viral dysregulation of cellular stasis, as host cell miRNAs,
including those specific to hematopoietic cells, have been found
to significantly affect cellular proliferation and differentiation, as
well as the immune response of mammals (Chen et al., 2004;
Fazi et al., 2005; Cobb et al., 2006; Li et al., 2007; Loffler et al.,
2007; Ivanovska et al., 2008; Johnnidis et al., 2008; Carissimi et al.,
2009; Faraoni et al., 2009; Huang et al., 2009; Lal et al., 2009;
Curtale et al., 2010). Thus, an infecting virus can induce a range
of host responses, such as resistance to apoptosis, an increase in
cellular proliferation, or alteration of transcriptional regulation,
to their benefit. Furthermore, some human miRNAs have also
been shown to directly target human endogenous retroviruses
(HERVs) and invading exogenous retroviruses (IERVs) includ-
ing HTLV-1 (Hakim et al., 2008). In the case of HIV-1, a cluster
of host miRNAs that are up-regulated in resting CD4+ T-cells
has been shown to target the 3′-region of the HIV-1 transcript
which contributes to latency in this cellular population (Huang
et al., 2007). Therefore, the viral manipulation of miRNA lev-
els also can affect either evasion of innate host immune response
through down-regulation of anti-viral miRNAs, or establishment
of a latently infected cell population through co-opting these
miRNAs. Indeed, alteration of host miRNA transcription levels
has been detected in other virally infected cells, such as those from
EBV infected patients (Cameron et al., 2008; Gatto et al., 2008).
One such host miRNA up-regulated by EBV, miR-155, also was
shown to aid in viral latency by suppressing NF-κB signaling (Lu
et al., 2008). More recently, one study showed the hematopoi-
etic specific miRNAs, including miR-223, miR-181a, miR-150,
miR-142.3p, and miR-155, were dysregulated in both in vitro and
in vivo samples of HTLV-1 infected cells (Bellon et al., 2009).
This dysregulation was found to favor differentiation of infected
cell lines as expression levels of different endogenous miRNAs
has been found to vary among cell types of different lineages
(Merkerova et al., 2008). Also, miR-155, miR-125a, miR-132, and
miR-146, which are regulatory components of the innate immune
response, were found to be dysregulated. Lastly, the response
of two of these dysregulated miRNAs, specifically miR-150 and
miR-223, diverged between the infected in vitro cell line and iso-
lated patient cells (Bellon et al., 2009). This is only one example in
which host miRNA profiles were shown to be altered in relation
to HTLV-1 infection and others will be described in more detail
later in the review.
EPIGENETIC REGULATION AND CHROMATIN REMODELING
TO ALTER HOST miRNA PROFILES
One of the strategies utilized by retroviruses to regulate both
viral and cellular transcription, including the transcription of
miRNA genes, is through the modulation of higher order chro-
matin structure, often through manipulating epigenetic markers.
This is important for retroviruses in particular, due to the need
for the provirus to integrate into the host genome, the efficiency
of which is governed by the presence of either a heterochromatic
or euchromatic state. HLTV-1 has been well documented to inter-
act with a variety of host cellular chromatin modifying enzymes,
such as histone acetyltransferases (HATs), histone methyltrans-
ferases (HMTs), and ATP-dependent chromatin remodelers, all
of which are manipulated by viral proteins to ensure a favor-
able transcriptional state. The interaction of the HTLV-1 viral
protein Tax with these cellular enzymes, as well as transcription
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factors, results in the activation of the viral promoter and the
production of viral transcripts. Similarly, the viral manipulation
of chromatin remodeling enzymes could also alter transcription
of cellular genes including those encoding miRNAs. Additionally,
due to the ability of Tax to manipulate chromatin structure and
the innate host cellular defense mechanism of RNAi to regulate
pathogen gene expression, there is most likely interplay between
these two competing mechanisms. Here, we also introduce the
reciprocal interaction of HTLV-1-induced epigenetic regulation
and chromatin remodeling with the host cellular RNAi response.
HTLV-1 INTERACTION WITH HATs
The viral transactivator, Tax, activates the HTLV-1 viral pro-
moter within the long terminal repeat (LTR) by interacting with
Tax-responsive elements (TREs) in the U3 region of the LTR.
Instead of binding to DNA directly, Tax induces transcription of
TREs, catalyzes post-translational modifications (PTMs) of TRE-
binding factors, and forms complexes with transcription factors.
Tax interacts with numerous important transcription factors and
cellular kinases but of these CRE Binding Protein (CREB) is key
to viral transcription (Caron et al., 1993; Suzuki et al., 1994;
Yin et al., 1995, 1998; Clemens et al., 1996; Colgin and Nyborg,
1998; Harrod et al., 1998; Gachon et al., 2000; Nicot et al., 2000;
Xiao et al., 2001; Kashanchi and Brady, 2005; Easley et al., 2010).
The interaction of Tax with CREB occurs in order to bind to
cis-acting replication element (CRE) enhancer sequences on the
viral promoter, which is a critical step in viral transactivation
and in the formation of the pre-initiation complex (Kwok et al.,
1996; Giebler et al., 1997; Kashanchi et al., 1998; Wu et al., 2004;
Easley et al., 2010). This interaction is also dependent on the
presence of the HATs CREB binding protein (CBP), p300, and
p300/CBP-associated factor (P/CAF) to activate HTLV-1 gene
expression. In addition to Tax interacting with these HATs to
directly activate viral transcription, the recruitment of these HATs
to the viral LTR promotes the covalent modification of histone
tails on adjacent nucleosomes to promote transcriptionally favor-
able chromatin state. In particular, CBP and p300 can acetylate
histones H2A, H2B, H3, and H4, resulting in a conformational
change. Additionally, Tax also reduces histone protein transcript
levels in HTLV-1 infected cells (Bogenberger and Laybourn, 2008;
Easley et al., 2010; Rahman et al., 2012). Beyond directly inter-
acting with and recruiting these HATs to the viral promoter, Tax
has also been shown to down-regulate numerous miRNAs that
target p300 and P/CAF, thereby boosting overall availability of
these HATs (Figure 1) (Rahman et al., 2012). In turn, the up-
regulation of p300 and P/CAF will allow for activation of other
host genes reliant on these chromatin remodelers including those
encoding miRNAs. Furthermore, Tax could also recruit CREB
and its associated HATs to other cellular genes, including those
encoding miRNAs, which contain sequences homologous to the
TREs, and up-regulate their transcription. In fact, Tax mediated
up-regulation via CREB signaling pathway activation has been
observed with the host gene β-catenin (Tomita et al., 2006).
HTLV-1 AND PROTEIN METHYLATION
Histone methylation often occurs as a signal of a repressed chro-
matin state as lysine residues on exposed histone tails cannot be
both acetylated and methylated simultaneously. Indeed, a hall-
mark of a heterochromatin state is often di- or tri-methylation of
H3 at residue K9 (H3K9me2/3). Conversely, histone methylation
FIGURE 1 | HTLV-1 dysregulation of host miRNA profiles. HTLV-1
infected cells selectively up- and down-regulate numerous host cell miRNAs.
Specifically, several miRNAs targeting the HATs P/CAF and p300 are
decreased in HTLV-1 and Tax transfected cells, while other miRNAs targeting
pro-apoptotic (TP53INP1) and immunomodulating genes (MICB) are
up-regulated. The dysregulated miRNAs and target proteins detailed here
represent only a small fraction of the cellular pathways manipulated by the
HTLV-1 virus.
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can also be an indicator of transcriptional activation, such as
methylation of H3 at residue K4 (H3K4) (Ooi et al., 2007; Fan
et al., 2008; Meissner et al., 2008; Cedar and Bergman, 2009). Tax
interacts with the HMT SUV39H1 at the LTR of HTLV-1 infected
cells, which subsequently represses Tax transactivation, as well as
methylates H3K9, forming a heterochromatinized state (Kamoi
et al., 2006). Additionally, Tax has been shown to interact with
SMYD3, an H3K4 methyltransferase, influencing the subcellular
localization of Tax as well as enhancing Tax-dependent activation
of the NF-κB pathway (Yamamoto et al., 2011). Moreover, the
activation of the NF-κB pathway by Tax is a key mechanism by
which HTLV-1 can up-regulate several host miRNAs, as will be
discussed in detail later. Therefore, Tax association with SMYD3
is important in enabling this mechanism of viral manipulation of
the host miRNA profile. Furthermore, the interaction of Tax with
these cellular HMTs could also influence the epigenetic state of
cellular genes and hence alter the host miRNA profile.
HTLV-1 AND ATP-DEPENDENT CHROMATIN REMODELING ENZYMES
While the epigenetic regulation of histones and chromatin by
HATs and HMTs can induce conformational changes, more
significant nucleosomal alterations require yet another class of
chromatin remodelers. ATP-dependent chromatin remodeling
complexes (CRCs) are powerful molecular motors that use energy
derived from ATP hydrolysis to disrupt histone/DNA interac-
tions, thereby exposing nucleosomal DNA (Chiba et al., 1994;
Reyes et al., 1998). Several classes of CRCs have been isolated
from eukaryotic cells and all of them contain a related ATPase
motor subunit. The most well documented mammalian CRC
is the BAF [Brahma-related gene (BRG)/Brahma-associated fac-
tor] complexes which are homologous to the yeast SWI/SNF
(switching-defective/sucrose non-fermenting) complexes (De La
Serna et al., 2006). This complex is composed of one ATPase
subunit, either BRG1 or BRM and a multitude of other protein
subunits, all of which comprise their own chromatin-remodeling
complex which can either activate or repress chromatin remod-
eling, thereby altering transcription. Our laboratory previously
showed that BRG1 is essential for both Tax transactivation and
viral replication (Easley et al., 2010). When recruited by Tax,
the BRG1-containing CRC, PBAF, is responsible for nucleosomal
remodeling at the LTR, specifically, the removal of Nuc-1, pro-
moting active viral transcription. Alternately, Tax could recruit
these ATP-dependent CRCs to other locations within the host
genome and alter the nucleosomes within the promoter of other
genes including those encoding miRNAs.
MODULATION OF CHROMATIN REMODELING BY miRNA WITH HTLV-1
INFECTION
Chromatin remodeling in the context of a retroviral infection
begins when the provirus integrates into the host genome. The
efficacy of the integration is based on the chromatin structure
at the site, often dictating an active infection (insertion into
a euchromatic region) or a latent infection (insertion into a
heterochromatic region). It has recently been shown that the
RNAi machinery in coordination with endogenous miRNAs or
exogenous siRNA can play a role in chromatin structure and reor-
ganization, especially in the context of cancer and viral infections.
As will be discussed in detail later, TGS can occur through RNA
Pol II in an RNAi-dependentmanner by recruitment of epigenetic
modifiers (Kato et al., 2005; Merkenschlager and Wilson, 2008).
Interestingly, miRNAs originate from promoters that are subject
to the local chromatin structure and the miRNAs produced can
ultimately affect the native chromatin structure creating a regu-
latory feed-back loop. In regards to retroviruses, the expression
profile of miRNAs is dramatically different in cells infected with
HTLV-1 and HIV-1, as compared to their uninfected counter-
parts. Furthermore, virally encoded miRNAs have been identified
as being produced from integrated HIV-1 as well as other RNA
viruses and, therefore, it is possible that HTLV-1 encodes as of
yet undiscovered viral miRNAs (Ouellet et al., 2008; Klase et al.,
2009; Perez et al., 2010; Narayanan et al., 2011; Althaus et al.,
2012; Kincaid et al., 2012; Schopman et al., 2012). Indeed, the
RNAi pathway is an appropriate target for retroviruses to manip-
ulate in order to regulate proteins, such as transcription factors
and chromatin remodelers, that are needed for viral replication
or to establish latency.
A recent study investigated transcription factor profiles as well
as profiles of proteins and miRNAs which are Tax-responsive in
a stably integrated HTLV-1 LTR T cell clone (Rahman et al.,
2012). This study identified that not only does Tax increase the
activation of substrates and factors associated with chromatin
remodeling, but it down-regulates miRNAs which target factors
needed for chromatin remodeling. Specifically, several substrates
for HATs and CRCs were up-regulated, including E2F1, GATA,
TFIID, nuclear receptors, glucorcorticoid receptors, retinoid X
receptors, and vitamin D receptors. Other previously identi-
fied HTLV-1 associated transcription factors, such as CREB and
Sp1, were also up-regulated. In regards to miRNA profile alter-
ation, miR-135b, miR-149, andmiR-872, which specifically target
P/CAF, were down-regulated in the presence of Tax, as well as
miR-149, miR-872, and miR-873, which target p300 (Figure 1).
It is hypothesized that Tax imparts this up-regulation of HATs
through suppression of Dicer or Drosha, key RNAi components.
This type of suppression has previously been seen in HIV-1, as
well as with primate foamy virus type 1 (Bennasser et al., 2005;
Lecellier et al., 2005). While a comparable mechanism has yet
to be fully elucidated in regards to HTLV-1, potential pathways
have been identified. Specifically, recent studies from our lab have
shown Tax associates with Drosha and likely targets it for pro-
teasomal degradation (Van Duyne et al., 2012). The mechanism
of Tax mediated proteasomal degradation has previously been
observed with other cellular proteins including retinoblastoma,
and Tax actually boosts the proteolytic activity of the proteasome
(Hemelaar et al., 2001; Kehn et al., 2005). This novel mechanism
of Drosha suppression reduces the ability to process pri-miRNA
into mature miRNAs, thereby presenting a probable mechanism
for the global down-regulation of most miRNAs observed with
Tax expressing cells (Figure 2) (Rahman et al., 2012).
POTENTIAL TRANSCRIPTIONAL GENE SILENCING IN HTLV-1
INFECTIONS
Transcriptional gene silencing (TGS) occurring through RNA
complementary to gene promoters was first observed and
examined in detail in plant species starting around 2000
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FIGURE 2 | Tax mediated proteasomal degradation of Drosha.
Tax binds to Drosha and drives subsequent ubiquitination and
proteasomal degradation of the protein. This reduction in cellular levels
of Drosha in turn leads to global down-regulation of host miRNAs by
minimizing the enzymatic machinery to convert Pri-miRNAs to
Pre-miRNAs.
(Mette et al., 2000). In 2004, studies utilizing S. pombe fission
yeast first identified several of the components of the RNAi-
dependent RITS complex that are required for TGS and postu-
lated a mechanism of action (Noma et al., 2004; Verdel et al.,
2004). That same year, mammalian species were shown to carry
the same molecular mechanism of gene silencing. Initial evidence
of TGS via small ncRNAs in mammals was established using a
model system comprised of an elongation factor 1 alpha (EF1α)
promoter fused to GFP, which was integrated into the genome of
human 293T cells with a feline immunodeficiency virus lentiviral
vector. The EF1α-GFP reporter was then silenced by transfection
of EF1α promoter targeting siRNA and the silencing mechanism
was shown to be induced by DNA methylation (Morris et al.,
2004). Another early study showed that induced TGS could be
achieved with shRNAs complementary to the promoter region or
up to 23 nucleotides down-stream of the transcriptional start site
of the RASSF1A tumor suppressor gene. The observed TGS in this
experiment also caused low levels of DNA methylation and par-
tial gene silencing in stably transfected HeLa cultures (Castanotto
et al., 2005). A relevant comprehensive review of TGS in HIV-1
infections has recently been published (Sampey et al., 2012).
Molecular mechanism of transcriptional gene silencing in
mammalian cells
While the molecular mechanisms involved in mammalian TGS
have still not been clearly defined, a set of studies by Kim et al.
helped to elucidate several of the proteins necessary for this mode
of gene silencing (Kim et al., 2006). In their studies, mammalian
TGS was examined using both transfected siRNA and stably inte-
grated shRNA that targeted either a GFP reporter construct under
the control of the CCR5 promoter or the endogenous RASSF1A
promoter. Chromatin immunoprecipitation (ChIP) experiments
showed enrichment of H3K9me2 at the target promoter of the
siRNA, as well as in proximal flanking DNA up to 300-bp down-
stream of the target promoter. Furthermore, this boost in the
H3K9me2 epigenetic marker was found to increase over a 24 h
period post-transfection. Moreover, Ago1 was also enriched at
the target promoter and flanking DNA but, unlike the H3K9me2
enrichment, the Ago1 enrichment was transient, peaking at 6 h
post-transfection and then rapidly decreasing over the following
18 h. It was also found that the siRNA mediated knockdown of
Ago1 disrupted both Ago1 and H3K9me2 enrichment at the tar-
get promoter following siRNA transfection indicating the role of
Ago1 in recruiting siRNA and/or the necessary HMTs to the pro-
moter. The involvement of Ago1, as well as Ago2, in mammalian
TGS was also found to be required for the formation of the RITS
complex in other TGS studies (Janowski et al., 2006; Ahlenstiel
et al., 2012). The most recent of these studies showed that HIV-1
promoter targeting siRNAs were found to co-localize with RITS-
like component Ago1 in the nucleus and Ago2 at the inner nuclear
membrane. This work also indicated the involvement of actin in
the transport of this RITS-like complex and showed siRNA speci-
ficity in this translocation as scrambled siRNA was retained in the
cytoplasm (Ahlenstiel et al., 2012).
Beyond Ago1 and Ago2, TRBP2 was also found to be enriched
at the target CCR5 promoter after siRNA transfection. Similar
to the Ago1 knockdown, the knockdown of TRBP2 via siRNA
also blocked subsequent TGS inhibition of the reporter gene
mRNA. These data therefore, clearly demonstrated the mechanis-
tic necessity of TRBP2 in RNAi-induced TGS (Kim et al., 2006).
It was also demonstrated that Ago1 was able to co-precipitate
with Pol II containing an unphosphorylated CTD after degrad-
ing associated RNA, thereby showing a direct protein-protein
interaction between these two components. Finally, the histone
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methyltransferase EZH2, a component of the Polycomb silenc-
ing machinery, was also found to be enriched at siRNA targeted
endogenous promoters indicating its potential role in the epige-
netic modification related to TGS. As EZH2 boosts H3K27me3
levels, this isoform of H3 was also found to be enriched at the tar-
geted promoters (Kim et al., 2006). Furthermore, EZH2 is also
able to bind and recruit DNMTs via its homology II domain,
thereby providing yet another mechanism by which additional
epigenetic silencing may occur (Vire et al., 2006).
Additionally, experiments targeting the endogenous EF1α pro-
moter with nuclear targeted siRNA also showed an increase in
the levels of H3K9me2 and H3K27me3. The observed increase
in the H3K9me2 was found up to 720-bp down-stream of the
targeted siRNA site, demonstrating the spread of the induced epi-
genetic changes to DNA distal to the target site. Furthermore, a
Pol II inhibitor effectively blocked the increase in the TGS asso-
ciated epigenetic marker, H3K9me2, indicating the requirement
for Pol II in siRNA mediated TGS. It was also found that the
antisense strand and double stranded siRNA targeting the EF1α
promoter also bound to the DNA methyltransferase, DNMT3A.
Additional experiments with a HIV-1 LTR reporter cell line fur-
ther showed that antisense siRNA alone targeting the U3 region
of the LTR was sufficient to down-regulate the reporter activity
(Weinberg et al., 2006).
Endogenously induced TGS in retroviral infections
While numerous studies of TGS have been conducted utilizing
exogenous small ncRNAs, such as siRNA and shRNA, very little
evidence links endogenously produced ncRNAs to this important
gene expression altering pathway. One study depicted the bidirec-
tional transcription of genes as generating competing sense and
antisense RNA strands that could alter gene expression by con-
trolling TGS (Morris et al., 2008). In this model, the antisense
strand expression could down-regulate the transcription of the
complimentary gene through recruitment of Ago1 and the repres-
sive H3K27me3 epigenetic marker to the sense strand promoter.
Conversely, reduction of the antisense strand using siRNA mini-
mized negative epigenetic regulation of the sense strand, thereby
boosting sense mRNA transcription.
In relation to TGS in retroviral infections, numerous stud-
ies have identified antisense transcripts and antisense proteins
produced by HIV-1 and HTLV-1 over the past several decades
(Miller, 1988; Larocca et al., 1989; Michael et al., 1994; Vanhee-
Brossollet et al., 1995; Peeters et al., 1996; Tagieva and Vaquero,
1997; Briquet and Vaquero, 2002; Bentley et al., 2004; Ludwig
et al., 2006; Satou et al., 2006; Landry et al., 2007; Yeung et al.,
2009; Bansal et al., 2010; Clerc et al., 2011; Lefebvre et al., 2011;
Schopman et al., 2012). Building upon this work, it was recently
shown that in HIV-1, the U3 region of the 3′ LTR contains a
promoter that generates a 2.6 kb antisense RNA (asRNA) with
transcriptional termination within the Env gene. The promoter of
this viral antisense transcript is driven by a NF-κB enhancer site
that is responsive to TNFα treatment but not Tat. Furthermore,
its over-expression led to repression of HIV-1 replication for up
to a month and, conversely, siRNA repression of the asRNA up-
regulated HIV-1 replication. While the mechanism by which the
HIV-1 asRNA inhibits viral replication was not fully elucidated, it
was shown that viral entry and integration were likely not inhib-
ited by asRNA over-expression, but that sense strand expression
was inhibited (Kobayashi-Ishihara et al., 2012).
Similarly, HTLV-1 is known to transcribe an asRNA that
encodes the viral protein HBZ. The HBZ gene has further been
shown to effect cells through a bimodal mechanism by which
both the protein product and the asRNA transcript have distinct
functionalities (Satou et al., 2006). Specifically, while the HBZ
protein inhibits Tax-mediated transactivation and viral transcrip-
tion, the HBZ asRNA causes increased proliferation of T cells.
Furthermore, mutational analysis showed that the first stem-
loop structure of the HBZ asRNA was required for the observed
growth-promoting activity, although initial attempts at detecting
miRNAs derived from this structure were unsuccessful. It has also
been shown that the vast majority of the HBZ asRNA is retained
in the nucleus indicating the asRNA functionality as a ncRNA reg-
ulator may be predominant (Rende et al., 2011). Additionally, it
has also been shown that the levels of the HBZ asRNA positively
correlated with disease severity in patients exhibiting HAM/TSP
(Saito et al., 2009). While the studies of the HBZ gene to date
have attributed the inhibition of viral transcription solely to the
protein product, it is possible that the asRNA transcript could
also function in an inhibitory fashion similar to that observed in
HIV-1. Overall, these findings could demonstrate that the asRNA
transcribed by the HTLV-1 provirus could function similarly to
the model of competing sense and antisense described earlier. In
order to demonstrate such a mechanism in regards to an HTLV-1
infection, though, further studies showing asRNA-induced TGS
and concurrent recruitment of Ago1 and/or repressive epigenetic
markers are necessary.
TAX MEDIATED ACTIVATION OF NF-κB TO ALTER HOST
miRNA PROFILES
Another mechanism by which HTLV-1 may manipulate the
host cell miRNA expression profile is through the activation of
host transcription factors. Important transcription factors and
cellular kinases which interact directly with the viral protein
Tax are CREB, serum-responsive factor (SRF), NF-κB, Cyclins
D2 and D3, mitotic checkpoint regulators (MAD1), cyclin-
dependent kinases (CDKs), the CDK inhibitors p16INK4A and
p21(WAF1/CIP1), and the tumor suppressor p53 (Caron et al., 1993;
Suzuki et al., 1994; Yin et al., 1995; Clemens et al., 1996; Colgin
and Nyborg, 1998; Harrod et al., 1998; Yin et al., 1998; Gachon
et al., 2000; Nicot et al., 2000; Xiao et al., 2001; Kashanchi and
Brady, 2005; Easley et al., 2010). Of these, dramatic activation
of both the canonical and non-canonical pathways of NF-κB is
a hallmark of HTLV-1 infection and is a result of direct interac-
tion between Tax and the NF-κB regulatory subunit IKKγ (Sun
and Yamaoka, 2005; Yasunaga and Matsuoka, 2011). This inter-
action results in a constant activation of the NF-κB cascade.
Furthermore, the NF-κB cascade promotes the transcription of
a number of cellular genes that control a wide variety of cellular
processes, including cellular proliferation and survival. The cas-
cade is divided into two pathways, canonical and non-canonical.
The two distinct IKK complexes associated with these pathways
are either comprised of two subunits of IKKα, or, alternatively,
one of IKKα, one of IKKβ, and two subunits of IKKγ, in the
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case of the non-canonical and canonical pathways, respectively.
In either case, activation of the IKK complex results in the inacti-
vation of an inhibitor of NF-κB (IκB) family protein. This in turn
results in the localization of RelA and p50 (canonical pathway) or
RelB and p52 (non-canonical pathway) to the nucleus. This cas-
cade subsequently up-regulates transcription at κB promoter sites
in the chromatin (Lo et al., 2006; Shembade andHarhaj, 2010). As
numerous miRNA promoters are positively regulated by NF-κB,
it can be inferred that the activation of NF-κB by Tax increases the
expression of several host cell miRNAs (Figure 3) (Li et al., 2012b;
Lukiw, 2012; Wang et al., 2012). One specific example is miR-155
which has been found to be up-regulated in HTLV-1 infected cells,
as well as in a tumor necrosis factor α (TNFα) stimulated cell
line through an NF-κB pathway (Bellon et al., 2009; Liu et al.,
2011). While this mechanism may explain the up-regulation of
several host miRNAs, examination of reporter constructs under
the control of promoters from the various up-regulated miRNAs
in HTLV-1 infected cells would verify exactly which of these are
regulated via NF-κB.
THE ROLE OF miRNA IN HTLV-1 ONCOGENIC SIGNALING
In addition to being the first identified human retrovirus, HTLV-
1 is also currently the only known oncogenic human retrovirus
causing a clinical condition known as ATL (Ruggero et al., 2010).
ATL is an aggressive disease state that is highly resistant to cur-
rent forms of chemotherapy and, consequently, usually results in
the death of the patient (Tsukasaki et al., 2007). While the com-
plete mechanisms of oncogenesis and tumorgenesis in HTLV-1
infected individuals has yet to be fully elucidated, a significant
body of knowledge has been developed over the past 35 years.
The virally encoded 40 kDa transactivator protein, Tax, has been
shown to immortalize T cells both in vitro and in vivo in the
absence of other viral factors and, thus, has become the focus
of much research into HTLV-1-mediated oncogenesis (Pozzatti
et al., 1990; Tanaka et al., 1990; Grossman et al., 1995). In recent
years, however, studies have expanded beyond a Tax-centered
focus and have postulated that Tax alone is not responsible for
cellular transformation but rather functions in conjunction with
some other viral or cellular factor. Investigations in to this arena
have detailed a number of Tax interactions that may play a role
in cellular transformation and of particular interest is the role of
miRNA in cellular transformation (Table 1).
ALTERED miRNA EXPRESSION CAN PROMOTE ONCOGENESIS
The current understanding of miRNA dynamics within a healthy
cell indicates that the RNAi machinery functions by modulating
numerous varied cellular processes simultaneously since a single
miRNA can target several different mRNAs. Consequently, the
up- or down-regulation of one or more miRNA will result in a
corresponding shift in balance for several pathways. In the case of
HTLV-1 infected cells, the virus alters the regulation of a number
of miRNAs in order to promote cell survival and proliferation.
FIGURE 3 | Protein-protein interactions of HTLV-1 Tax with members
of the NF-κB family of transcription factors. Dysregulation of the
canonical pathway occurs with the interaction of ubiquitinylated Tax to the
cytoplasmic IKK complex, specifically binding to the IKKγ subunit.
This interaction results in the phosphorylation of IκB, as well as the
ubiquitination and subsequent degradation of IκB through the proteasome
pathway. RelA is subsequently activated and translocates into the nucleus
where SUMOylated Tax recruits RelA to Tax-nuclear bodies, driving
Tax-mediated NF-κB transcription. Similarly, ubiquitinylated Tax interacts
with the IKKα complex to induce the processing of p100 to p52 within the
non-canonical pathway. This promotes the phosphorylation, ubiquitination,
and subsequent proteasomal degradation of p100, as well as the
recruitment of RelB to the nucleus for activation of Tax-mediated NF-κB
transcription. Xcr, transcription.
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Table 1 | An abbreviated list of deregulated host miRNAs, their target
mRNA, and subsequent biological effect in HTLV-1 infection.









miR-132 Down p300 Increase viral
transcription
AChE Pro-inflammatory
miR-143-p3 Up PKA Proliferation
GRα Proliferation
miR-146a Up Unknown Proliferation
miR-149 Down p300 Increase viral
transcription
miR-155 Up TP53INP1 Anti-apoptotic
Unknown Increase interferon-γ
miR-873 Down p300 Increase viral
transcription
Numerous host miRNAs are either up- or down-regulated in HTLV-1 infected
cells through varied molecular mechanisms. Listed here are several deregulated
host miRNAs found to play roles in the oncogenic or neurodegenerative dis-
eases associated with HTLV-1. Additionally, important cellular targeted mRNAs
are listed, as well as the resultant biological effect of the miRNA deregulation
for those miRNAs that have been characterized.
While a complete understanding of viral interaction with cellu-
lar miRNAs remains to be elucidated, a number of significant
interactions have been observed.
One key finding was the up-regulation of miR-93 in HTLV-1
infected cells. A number of groups have reported increased
expression of miR-93 in a variety of tumors, as well as in
HTLV-1 infected cell lines and ATL patient samples, indicating
that this miRNA plays a significant role in cellular transformation
(Yanaihara et al., 2006; Blenkiron et al., 2007; Ambs et al., 2008;
Nam et al., 2008; Petrocca et al., 2008; Yeung et al., 2008; Kan et al.,
2009; Li et al., 2009; Ruggero et al., 2010). In uninfected cells,
miR-93 is involved in the control of TransformingGrowth Factor-
β (TGF-β) mediated cell cycling. MiR-93 expression is induced by
the S phase regulator protein E2F1, which is then targeted and
subsequently down-regulated by miR-93. Another vital cell cycle
promoter, p21(WAF1/CIP1), is also a target of miR-93 (Figure 1).
p21(WAF1/CIP1) is up-regulated by the interaction of Tax with the
anaphase-promoting complex/cyclosome (APC/C) consequently
causing a phenomenon known as Tax-induced rapid cellular
senescence (Tax-IRS). Tax-IRS causes newly infected cells to
rapidly progress through the cell cycle and ultimately undergo
premature apoptosis. However, HTLV-1 transformed cells expe-
rience cell cycle arrest despite continued expression of Tax (Kuo
and Giam, 2006; Yang et al., 2011a; Zhi et al., 2011). Thus, the
observation that miR-93 is up-regulated in HTLV-1 cell lines
and ATL samples suggests that the virus may hijack the cellular
RNAi machinery in order to prevent unchecked cellular senes-
cence and promote cellular immortalization. Furthermore, major
histocompatibility complex class I chain-related B (MICB) has
been identified as a significant target of miR-93 (Figure 1). MICB
is a ligand recognized by the natural killer group 2 receptor mem-
ber D (NKG2D), a receptor found in natural killer cells that are
responsible for mediation of cell killing (Ruggero et al., 2010;
Elias andMandelboim, 2012). By inducing the over-expression of
miR-93, transformed cells could effectively down-regulate MICB
and, thereby, promote evasion of the host tumor surveillance
activity; thus, likely contributing to the continued survival of
HTLV-1 infected cells.
Yet another host miRNA, miR-223, was shown to be up-
regulated in HTLV-1 infected cells from ATL patients (Bellon
et al., 2009). The over-expression and increased serum levels
of miR-223 has been observed in numerous in vitro models
and clinical samples from patients with varying carcinomas (Yao
et al., 2009; Li et al., 2010, 2011b, 2012a; Xu et al., 2011; Yang
et al., 2011b; Kurashige et al., 2012). Moreover, miR-223 over-
expression in both in vitro and in vivo gastric carcinoma models
increased cell adhesion and invasion, with increased metastasis
to lymph nodes (Li et al., 2011b). This increase in invasiveness
and metastasis was shown to be due to miR-223 targeting of
the 3′-UTR of the anti-migration factor erythrocyte membrane
protein band 4.1-like 3 (EPB41L3). While this data would sug-
gest a role of miR-223 in promoting ATL oncogenesis, other
studies have found miR-223 to be an anti-oncogenic marker (Li
et al., 2011a; Wu et al., 2012). One of these studies demonstrated
that over-expression of miR-223 could in fact decrease cellular
migration and invasiveness by targeting the neurotrophic factor
Artemin (Li et al., 2011a). Furthermore, in the study that found
increased expression of miR-223 from ATL patients, they also
found decreased miR-223 expression in HTLV-1 infected model
cell lines (Bellon et al., 2009). This contradictory data regarding
miR-223 demonstrates the complicated and sometimes divergent
functionalities of miRNAs due to their ability to target numerous
mRNAs from varied cellular pathways. It also shows the difficulty
in linking observations made from in vitromodel cell lines to cells
infected in highly complex in vivo systems. In order to determine
the true mechanism of action with regards to miR-223 in HTLV-1
infected patients, more studies are required in the near future.
Additionally, up-regulation of miR-143-p3 has also been
observed in both in vitro HTLV-1 infected cell lines and in vivo
cells from ATL patients (Bellon et al., 2009). Beyond the observed
up-regulation in the HTLV-1 infected cells, miR-143-p3 has also
been found to be up-regulated in T-leukemic cell lines, as well
as from T-leukemic cells isolated from T cell acute lymphoblas-
tic leukemia (T-ALL) (Lv et al., 2012). From the study regarding
increased miR-143-p3 in T-ALL patients, it was found that the
mechanism of action for leukemogenesis by this miRNA was due
to reduced cAMP activation of protein kinase A (PKA) and direct
targeting of the glucocorticoid receptor α (GRα) mRNA 3′-UTR.
Furthermore, the oncogenic virus, Kaposi’s sarcoma associated
herpesvirus (KSHV), was also found to encode a viral miRNA,
miR-10Ka, that has high homology to the seed region of miR-
143-p3 variants and, therefore, targets many of the same mRNAs
(Gottwein et al., 2011).
The host miRNA, miR-155, has also been identified as impor-
tant to HTLV-1 mediated cellular transformation. Increased
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expression of miR-155 in transformed cells is not surprising as
it has been observed in other oncogenic viruses, such as EBV
(Metzler et al., 2004). Furthermore, some viruses, specifically
KSHV andMarek’s disease virus, even produce viral miRNAs that
mimic miR-155 (Gottwein et al., 2007; Skalsky et al., 2007; Zhao
et al., 2011). Mechanistically, miR-155 targets Tumor Protein
53-Induced Nuclear Protein 1 (TP53INP1), which promotes cell
cycle arrest and subsequent apoptosis (Figure 1). Therefore, the
inhibition of TP53INP1 by miR-155 induces cellular transforma-
tion (Ruggero et al., 2010). Moreover, the observed up-regulation
of miR-155 in viruses such as EBV is a direct result of activation
of the NF-κB pathway by viral proteins. This is comparable to the
mechanism of NF-κB activation via Tax described earlier.
The maximal level of NF-κB activation by Tax provides the
beginning to what could prove to be another fascinating phe-
nomenon in miRNA mediated oncogenesis as miR-146a and
miR-21 are both regulated by the NF-κB pathway and are report-
edly up-regulated in HTLV-1 infected cells. The up-regulation
of miR-146a and miR-21 is likely important in the oncogene-
sis of HTLV-1 infected cells as these miRNAs have been shown
to elicit anti-apoptotic functionality and are over-expressed in
a number of human cancers (He et al., 2005; Volinia et al.,
2006; Selcuklu et al., 2009; Tomita et al., 2012). The connec-
tion between NF-κB activation and HTLV-1 mediated regulation
of cellular miRNA will require further study but could pro-
vide novel insight into the dynamics of Tax mediated cellular
transformation.
TAX DOWN-REGULATES SELECT miRNAs TO PROMOTE CONTINUOUS
VIRAL TRANSCRIPTION
As described earlier, transcription of the HTLV-1 viral genome is
largely carried out by the formation of the Tax/CREB/CBP/p300
complex which binds to the TRE-1. For Tax activated tran-
scription to proceed, Tax must dimerize and recruit the CREB
dimer, which interacts directly with the viral CRE in the TRE-
1. Following the formation of the Tax/CREB complex, CBP/p300
is recruited in order to acetylate the histones of proximal nucle-
osomes and, thus, promote a chromatin remodeling event that
results in an euchromatic state. This open chromatin structure
provided by CBP/p300 is vital for transcription to proceed.
Recent work by Rahman et al. has provided evidence that Tax
down-regulated miRNAs that target p300 (Rahman et al., 2012).
Utilizing a stably integrated HTLV-1 LTR-luciferase reporter con-
struct in Jurkat cells, they demonstrated a down-regulation of 35
different miRNAs in the presence of Tax. Amongst these, miR-149
and miR-873, which target p300, were demonstrated to be down-
regulated by 7-fold and 5-fold respectively in HTLV-1 infected
MT-2 cells, as compared to uninfected Jurkat cells. This obser-
vation demonstrates the role of Tax in hijacking the cellular RNAi
machinery to modulate viral gene expression. The ability of Tax
to manipulate the RNAi machinery is further supported by recent
work from our lab, which reported that Tax significantly reduces
the expression of Drosha, a crucial enzyme in the formation of
mature miRNA. Through a series of transfection experiments, we
demonstrated that Tax and Drosha co-localize in the nucleus and
that Tax prevented the cleavage of pri-miRNA by Drosha (Van
Duyne et al., 2012).
The studies reviewed here indicate that Tax-mediated regu-
lation of miRNA expression is not simply a down-stream by-
product of NF-κB or any other transcription factor activation by
Tax. Rather it implicates Tax in a direct role in regulation of cel-
lular miRNA. Even more compelling is the notion that this could
provide an explanation for the low levels of Tax expression seen in
older transformed cells as compared to the strong Tax expression
observed in newly transformed cells. Further research into the Tax
and miRNA interplay is necessary to fully elucidate the under-
lying molecular mechanisms; however, the data to date indicates
that Tax is required to induce cellular transformation by initiating
a cascade effect via miRNA dysregulation. The host cell miRNA
dysregulation results in cellular immortalization and immune
evasion, while still maintaining viral transcription. Furthermore,
once cellular immortalization is established through the miRNA
profile alteration, Tax is not required for transformation mainte-
nance as it is difficult, if not impossible, for the cell to correct the
imbalance (Jeang, 2010). The role of Tax in miRNA regulation is
a recent and novel line of inquiry and continued research will be
required to fully understand this exciting avenue of research.
ALTERED miRNA EXPRESSION CAN PROMOTE HAM/TSP
In addition to inducing oncogenesis, HTLV-1 up-regulated miR-
NAs may also contribute to the development of the other
major clinical manifestation of this virus, HAM/TSP (Table 1).
Specifically, miR-155, which is up-regulated in HTLV-1 infected
cells, has also been associated with other neuro-inflammatory dis-
eases such as multiple sclerosis (Paraboschi et al., 2011). This
contribution of miR-155 to the onset of HAM/TSP may be in
part due to its ability to increase production of interferon-γ,
which is a characteristic feature of the disease (Yamano et al.,
2009; Trotta et al., 2012). Furthermore, another study showed
the up-regulation of miR-155 could be effectively attenuated
through the treatment of the HTLV-1 infected MT-2 cell
line with a high dose ascorbic acid regimen. Moreover, treat-
ment with high doses of ascorbic acid also exhibited signifi-
cant cell death and anti-proliferative effects on both in vitro
and ex vivo cultures of HTLV-1 infected cells (Moens et al.,
2012).
Another miRNA that is likely involved in the HAM/TSP
pathogenesis is miR-132. Specifically, miR-132 was shown to
be down-regulated in HTLV-1 infected cell lines, samples from
ATL patients, and Tax transfected cell lines (Bellon et al., 2009;
Rahman et al., 2012). Functionally, miR-132 has been shown to
target acetylcholine esterase (AChE) mRNA, and therefore, the
down-regulation of miR-132 boosts AChE activity and subse-
quently reduces acetylcholine levels (Shaked et al., 2009). It has
been shown that in response to pro-inflammatory stimulus, the
vagus nerve will release acetylcholine which in turn will atten-
uate pro-inflammatory cytokine release such as TNF, IL-6, and
IL-18 from macrophages and can limit the influx of activated T
cells into simple motor neuron lesions (Borovikova et al., 2000;
Nicolussi et al., 2009). The activation of the anti-inflammatory
pathway by acetylcholine has been demonstrated to be via bind-
ing to the nicotinic acetylcholine receptor α-7 subunit (Wang
et al., 2003). Moreover, the down-regulation of miR-132 has also
been observed in tissue samples of Alzheimer’s disease patients
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linking this miRNA to another pro-inflammatory neurodegen-
erative condition (Cogswell et al., 2008). It is also interesting to
note that miR-132 targets p300, which as previously described is
essential to HTLV-1 proviral transcription and, therefore, likely
boosts viral replication. Again, this potential duel functionality
of miR-132 demonstrates the complexity of the varied potential
effects-induced by dysregulation host miRNA profiles.
CONCLUSIONS
The manipulation of host miRNAs and RNAi machinery, as
well as encoding of viral miRNAs by human pathogenic viruses
has only recently come to light. Due to the diverse cellular
pathways controlled by miRNAs, the hijacking of the RNAi
molecular machinery and alteration of host miRNA profiles rep-
resents a significant and diverse mechanism by which viruses
can progress through their life cycle and effect varied disease
states in the host organism. Here, we examined recent find-
ings that show the human retrovirus, HTLV-1, does indeed
alter the miRNA profiles of infected cells which contributes to
cellular transformation and leads to the associated ATL and
HAM/TSP disease states. Furthermore, we show that alteration
of chromatin by viral proteins and host cell miRNAs can con-
tribute to the dysregulation host cell miRNA expression and
likely serves as a key mechanism by which the virus manip-
ulates host miRNA profiles. While recent discoveries validate
the importance of HTLV-1 mediated variation in miRNA lev-
els, there is still much to be elucidated in this novel field
of study. Moreover, a better understanding of the molecular
mechanisms by which this viral manipulation occurs will aid
in the identification of potential points of therapeutic inter-
vention that could help eradicate this pathogen from infected
individuals.
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